Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor-Reference-Cited by-同舟云学术

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Published:2016-03-30 Issue:7 Volume:59 Page:3392-3408
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Menichincheri Maria¹,Ardini Elena¹,Magnaghi Paola¹,Avanzi Nilla¹,Banfi Patrizia¹,Bossi Roberto¹,Buffa Laura¹,Canevari Giulia¹,Ceriani Lucio¹,Colombo Maristella¹,Corti Luca¹,Donati Daniele¹,Fasolini Marina¹,Felder Eduard¹,Fiorelli Claudio¹,Fiorentini Francesco²,Galvani Arturo¹,Isacchi Antonella¹,Borgia Andrea Lombardi¹,Marchionni Chiara¹,Nesi Marcella¹,Orrenius Christian¹,Panzeri Achille¹,Pesenti Enrico²,Rusconi Luisa¹,Saccardo Maria Beatrice¹,Vanotti Ermes¹,Perrone Ettore¹,Orsini Paolo¹

Affiliation:

1. Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy

2. Accelera Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b00064

Reference49 articles.

1. The development of imatinib as a therapeutic agent for chronic myeloid leukemia

2. Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome